



Curriculum Vitae Europass

Personal information

Name /Surname Susanna Morano

Address

Università Sapienza, Dipartimento di Medicina Sperimentale, Endocrinologia
Viale del Policlinico, 155 - 00161 Roma - Italy
Tel/Fax +390649978381

Nationality Italiana

Occupational field/Current position Professore Associato di Endocrinologia, Dipartimento di Medicina Sperimentale (Clinica Medica V), Sapienza Università, Roma
Membro del Senato Accademico, Sapienza Università di Roma

Work experience

Dates 2008- present

Occupation or position held Professore Associato di Medicina Interna (2008-2013) e attualmente Professore Associato di Endocrinologia, Medico

Main activities and responsibilities Insegnamento, Attività clinica

Name and address of employer Università Sapienza, Facoltà di Medicina, Piazzale Aldo Moro, 5-00161, Roma

Sector Insegnamento in Corsi di Laurea, Specializzazione e Master, Facoltà di Medicina, Attività Assistenziale e di Ricerca

Dates 2001-2007

Occupation or position held Ricercatore di Endocrinologia, Attività clinica

Main activities and responsibilities Insegnamento, Attività clinica

Name and address of employer Università Sapienza, Facoltà di Medicina, Piazzale Aldo Moro, 5-00161, Roma

Sector Insegnamento in Corsi di Laurea, Specializzazione e Master, Facoltà di Medicina, Attività Assistenziale e di Ricerca

Dates 1990-2000

Occupation or position held Funzionario Tecnico (8° Livello)-Ricercatore di Endocrinologia, Attività clinica

Main activities and responsibilities Insegnamento, Attività clinica

Name and address of employer Università Sapienza, Facoltà di Medicina, Piazzale Aldo Moro, 5-00161, Roma

Sector Insegnamento in Corsi di Laurea, Specializzazione e Master, Facoltà di Medicina, Attività Assistenziale e di Ricerca

Dates 1985

Occupation or position held Research Visitor

Main activities and responsibilities Attività di ricerca

Name and address of employer Unit of Metabolic Medicine, King's College, Faculty of Medicine and Dentistry; London University, London, UK

Sector Ricerca clinica e di laboratorio

Dates 1983-1990

Occupation or position held Assegnista di ricerca

Main activities and responsibilities Ricerca di laboratorio e clinica

Name and address of employer Consiglio Nazionale delle Ricerche 5, Piazzale Aldo Moro, 00161, Roma

Sector Progetto Finalizzato: Prevenzione Nefropatia Diabetica

Education and training				
	Dates	1986		
	Title of qualification awarded	Specializzazione in Endocrinologia		
	Name and type of organisation providing education and training	Università "La Sapienza", Roma		
	Dates	1982		
	Title of qualification awarded	Specializzazione in Nefrologia		
	Name and type of organisation providing education and training	Università "La Sapienza", Roma		
	Dates	1978		
	Title of qualification awarded	Laurea in Medicina e Chirurgia, votazione 110/110 e la lode		
	Name and type of organisation providing education and training	Università "La Sapienza", Roma		
	Dates	1974-1978		
	Title of qualification awarded	Internati		
	Name and type of organisation providing education and training	Dipartimento di Medicina Interna "Baglivi", Ospedale "Santo Spirito", Lungotevere in Sassia, Roma		
	Mother tongue	Italiano		
	Other language Self-assessment	Understanding B2 Listening English Reading English	Speaking B2 Spoken interaction English Spoken production English	Writing B2 English

Personal skills and competences 1986-2011-
Partecipazione Comitato Scientifico/Organizzatore di Congressi:
- "XXII Annual Meeting of the European Association for the Study of Diabetes, EASD", Roma, 1986
- "Diabetic Complications '87", Roma, 1987
- Congresso SID-AMD Lazio, Bracciano (Roma), 2002
- Aggiornamento SID-AMD-Roma, 2002
- Congresso SID-AMD Lazio, Fiuggi (FR), 2004
- "New Therapeutic Options in Diabetes", Roma, 2008
- "Diabete tipo 2: dalla diagnosi al controllo metabolico ottimale", Roma, 2009
- "New Frontiers in Type 2 Diabetes: Incretin based therapy." Roma, 2009
- "Diabete tipo 2: controllo metabolico e prevenzione delle complicanze", Roma, 2010
- "New Frontiers in Type 2 diabetes: news and debates", Roma, 2010
- "Diabete tipo 2: la complessità della malattia nella pratica clinica", Roma 2011

Partecipazione a Clinical Trials come PI o Co-Investigator (partial list)

Aldose reductase inhibitor-Tolrestat (Wyeth-Recordati)
"PDE-5 Inhibition and cardiac remodeling (Pfizer-Sapienza University)
Doxazosin e fattori di crescita endoteliali/rimodellamento cardiaco in diabetici ipertesi (Pfizer Italia)
Bay 38-9456/10781 (Vardenafil, Bayer)
H6D-MC-LVEM IC351 (LY450190) – Lilly)
NN304-1632 (Novo Nordisk)
CLAF237A2308 (Novartis)
Protocollo CLAF237A2354 (Novartis)
ST261 BUC 2002 001 (Sigma Tau)
GUID/02/Glm-Dia/001 (Guidotti)
ALTI TUDE (Novartis)
FARM537JNE: Studio LIRICO (AIFA)
D1690C00004 (Astra-Zeneca)
ANA-1897 (Novo Nordisk)
CLAF237B224 (Novartis)
BI 1218.16 (Boehringer)
BI 1218.40 (Boehringer)
BI 1218.62 (Boehringer)
SOLVE NN304 3714 (Novo Nordisk)
UPGRADE NN304-1632 (Mario Negri Sud-Nov Nordisk)
RIACE (Renal Insufficiency And Cardiovascular Events)-SID Italia
SUMMER (Sapienza University Mortality and Morbidity Event Rate)- Sapienza University of Rome

Personal skills and competences 1995- Reviewer della rivista Diabetes, Nutrition & Metabolism
1996-1998-Reviewer della rivista Diabetes
2000-2004 Membro del Comitato Scientifico della Società Italiana di Diabetologia (SID) - Lazio
2001- Reviewer delle riviste Diabetes / Metabolism Research and Reviews, e Journal of Endocrinological Investigation
2005- Membro del Comitato Valutazione Ricerca, CINECA
2000-to date-Membro del Consiglio di Amministrazione della Fondazione Diabetes, Endocrinology and Metabolism (DEM) - Roma
2002-2006 Membro Gruppo di Studio Nefropatia Diabetica della SID
2005-2011-Membro della Commissione Assistenza della Facoltà di Medicina e Chirurgia Università di Roma Sapienza
2007-2008 -Reviewer per CINECA di PRIN 2007-2008
2009- Membro Commissione Aggiornamento Clinico-Scientifico della SIE
2010- Membro Commissione MIUR per conferma Ricercatori Universitari MED 09
Membro Albo dei Revisori Progetti di Ricerca del MIUR (2007-2012)
2012-Membro dei Revisori per la valutazione di progetti per conto del MIUR (2007-2012). Membro della commissione per la valutazione dei prodotti di ricerca (VQR 2004- 2010) per conto dell'ANVUR
2009-2012-Membro Della Commissione MIUR per la conferma dei Ricercatori del S.S.D. MED / 09
2010- Membro del Comitato Scientifico della Società Italiana per lo Studio dell'Aterosclerosi (SISA) - Lazio
Membro dell'Albo dei Revisori Progetti di Ricerca MIUR (2007-2010)
2011- Membro Editorial Review Board della rivista "Frontiers in Endocrinology"
2012 – Membro Revisori progetti MIUR. Membro Commissione valutazione prodotti ricerca VQR 2004-2010 (ANVUR)
2013-2016-Membro del Senato Accademico dell'Università Sapienza di Roma, in rappresentanza dei Professori Associati della Macroarea C
2013-Reviewer della rivista Minerva Endocrinologica
2014- Membro della Commissione del Senato Accademico per le chiamate dirette di Professori I e II fascia e Ricercatori TD tipo B
Membro della Commissione del Senato Accademico per la sostenibilità dell'attività didattica dei SSD
Reviewer della rivista Journal of Clinical Endocrinology and Metabolism
Membro del Comitato Scientifico di 4-Educational, Provider ECM (nr. 842) riconosciuto dal Ministero della Salute. www.4educational.it
Membro dei valutatori per conto dell'Università Sapienza dei progetti banditi dal Ministero dello Sviluppo Economico (MISE)
2015. Socio IBDO Foundation
Membro valutazione progetti MIUR: Register of Expert Peer Reviewers for Italian Scientific Evaluation (REPRISE)
Reviewer delle riviste Acta Diabetologica, Diabetes Research and Clinical Practice, Journal of Clinical Endocrinology and Metabolism, Journal of Endocrinological Investigation (2014-2016)
2016- RAM - Responsabile accademico della mobilità CL Scienze Infermieristiche "C"
Premi/riconoscimenti
1993-1995-Progetto Ricerca: "Alterazioni neuroelettrofisiologiche in corso di diabete mellito sperimentalmente indotto" (CNR 93.04543.04).
1997-Progetto Ricerca: "Il ruolo del fattore di crescita dell'endotelio vascolare (VEGF) nella nefropatia diabetica: effetti del trattamento con inibitori dell'angiotensin converting enzyme (ACEI) e con calcio-antagonisti" (Finanziato dall'Associazione Medici Diabetologi).
2003-Progetto Ricerca: Doxazosin e fattori di crescita endoteliali/rimodellamento cardiaco in diabetici ipertesi. Finanziato da Pfizer Italia
1983-to date Finanziamenti per progetti di ricerca da parte di MIUR, Ministero della Sanità/Salute, Regione Lazio
Membro Ordinario della Società Italiana di Diabetologia (SID), Società Italiana di Endocrinologia(SIE), dell'European Association for the Study of Diabetes (EASD)

Clinical Activities Policlinico Umberto I, Università La Sapienza, Roma
1990-1997 – Assistente Medico, Divisione di Endocrinologia, Istituto Clinica Medicina 2, Direttore Prof. D. Andreani
1997-2004 – Assistente Medico, Divisione di Endocrinologia, Istituto Clinica Medicina 2, Direttore Prof. U. Mario
2004-2012 – Dirigente Medico I livello, Divisione di Medicina Interna e Malattie Metaboliche, Dipartimento Medicina Interna e Specialità Mediche, Clinica Medica 2
2013- to date Dirigente Medico, Divisione Endocrinologia, Dipartimento di Medicina Sperimentale, Clinica Medica 5
2005-2011- Membro Commissione Assistenza, Facoltà di Medicina, Università La Sapienza, Roma
Dal 1990- Attività Clinica: Reparti, Ambulatori e DH Diabetologia-Endocrinologia, partecipazione a turni di guardia interdivisionali (notturni, festivi, superfestivi) in Reparti di Medicina Interna, Gastroenterologia, Nefrologia, Immunologia Clinica

Teaching skills Università Sapienza, Roma
Facoltà di Medicina, Patologia Integrata 3, Patologia Integrata 5, Medicina interna e chirurgia generale 3, Metodologia Medico Scientifica Integrata 2, CLM D
Infermieristica Clinica in Area Medica, Corso Laurea C
Infermieristica Clinica in Area Medica, Corso Laurea D
Scuola di Specializzazione in Endocrinologia e Malattie Apparato Respiratorio
Master II livello Diabetologia (fino al 2012)
Membro del Collegio dei Docenti del Corso di Dottorato di Ricerca in Scienze Endocrinologiche
Membro del Comitato Ordinatore della Scuola di Specializzazione in Malattie dell'Apparato Respiratorio

Relatrice di Tesi: Laurea in Medicina e Chirurgia, Specializzazione Endocrinologia, PhD in Scienze Endocrinologiche Metaboliche Andrologiche (SEMA)

Annexes Speaker in congressi nazionali e internazionali

Publications Pubblicazioni scientifiche: Autore di articoli scientifici pubblicati su riviste internazionali, citati in Science Citation Index (PubMed, www.ncbi.nlm.nih.gov/pubmed).
Autore di 55 capitoli in libri o manuali per studenti del Corso di Laurea in Medicina e Chirurgia

- 1) Di Mario U, Mancuso M, **Morano S**, Andreani D. Immunological mechanisms in diabetic microangiopathy: immune complexes related to insulin treatment, platelet factors and lymphocytes. *Diab Neph* 4,3,109-113,1985
- 2) Di Mario U, Mancuso M, **Morano S**, Pietravalle P, Napoli A, Gambardella S, Andreani D. Urinary immunoglobulins: a highly sensitive technique using polyclonal antibodies in solid phase. *Diab Neph* 4,4,172-175,1985
- 3) **Morano S**, Di Mario U, Pietravalle P, Mancuso M, Napoli A, Gambardella S, Cancelli A, Andreani D. Sottopopolazioni linfocitarie, cellule T attivate e immunocomplessi circolanti in pazienti diabetici con e senza microalbuminuria. *G It Diabetol* 6,1,151-152,1986
- 4) Di Mario U, Pietravalle P, Napoli A, **Morano S**, Mancuso M, Gambardella S, Andreani D. A sensitive routine assay for urinary albumin based on the competitive binding to anti-albumin antibodies in solid phase. *Horm Metab Res* 18,689-692,1986
- 5) Di Mario U, **Morano S**, Mancuso M, Pietravalle P, Napoli A, Gambardella S, Andreani D. Urinary immunoglobulin G: a routine and highly sensitive technique based on competitive binding. *J Clin Lab Immunol* 20,155-158,1986
- 6) Di Mario U, Tiberti C, Scardellato A, Arduini P, Pietravalle P, **Morano S**, Andreani D. A fluid-phase routine method for the detection of insulin- anti-insulin complexes. *Diabetes Research* 3,437-442,1986
- 7) **Morano S**, Cancelli A, Mancuso M, Sensi M, Negri M, Gambardella S, Di Mario U. Sensitive immunoenzymatic assay for urinary immunoglobulin subclasses of different pH: its significance in diabetic patients. *Diabetes Research* 6,181-185,1987
- 8) **Morano S**, Di Mario U, Cancelli A, Bacci S, Frontoni S, Napoli A, Falluca F, Gambardella S, Andreani D. The selective elimination of anionic immunoglobulins as a parameter of kidney damage in diabetes and diabetic pregnancy. *J Diab Compl* 2,1,2-4,1988
- 9) Pozzessere G, Rizzo PA, Valle E, Mollica MA, Meccia A, **Morano S**, Di Mario U, Andreani D, Morocutti C. Early detection of neurological involvement in type 1 and type 2 diabetes: Multimodal evoked potentials versus metabolic control. *Diabetes Care* 11,473-480,1988
- 10) Di Mario U, **Morano S**, Cancelli A, Frontoni S, Bacci S, Mancuso M, Gambardella S, Andreani D. Looking for additional markers to monitor diabetic nephropathy: A new ELISA using monoclonal antibodies for the detection of IgG. *Diabetes & Metabolism* 14,216-217,1988
- 11) Sensi M, Pricci F, De Rossi MG, **Morano S**, Di Mario U. D-lysine effectively reduces the in vitro non-enzymic glycation of proteins in vitro. *Clin Chem* 35,384-387,1989
- 12) Pozzessere G, Rizzo PA, Valle E, Mollica M, Sanarelli L, **Morano S**, Pietravalle P, Di Mario U, Morocutti C. A longitudinal study of multimodal evoked potentials in diabetes mellitus. *Diabetes Research* 10,17-20,1989
- 13) Di Mario U, **Morano S**, Cancelli A, Bacci S, Frontoni S, Pietravalle P, Gambardella S, Andreani D. New parameters to monitor the progression of Diabetic Nephropathy. *Am J Kidney Dis* XIII,1,45-48,1989
- 14) Sensi M, Pricci F, De Rossi MG, Bruno MR, **Morano S**, Capuozzo E, Di Mario U. Formation and ways of detecting advanced glycation end-products in isolated human glomerular basement membrane and human serum albumin non-enzymically glycosylated in vitro. *J Diab Compl* 3,88-91,1989
- 15) Gambardella S, **Morano S**, Cancelli A, Pietravalle P, Frontoni S, Bacci S, Di Mario U, Andreani D. Urinary IgG4: an additional parameter in characterizing patients with incipient diabetic nephropathy. *Diabetes Research* 10:153-157,1989
- 16) Di Mario U, Cancelli A, Pietravalle P, Altamore G, Mariani G, De Rossi MG, Bernardini G, Pasquale A, Borgia MC, Frontoni S, **Morano S**. Anionic versus cationic immunoglobulin clearance in normal subjects: a novel approach to the evaluation of charge permselectivity. *Nephron* 55:400-407,1990
- 17) Gambardella S, Frontoni S, Felici MG, Spallone V, Gargiulo P, **Morano S**, Menzinger G. Efficacy of antihypertensive treatment with indapamide in patients with non insulin-dependent diabetes and persistent microalbuminuria. *Am J Cardiol* 65:46H-50H,1990
- 18) Pozzessere G, Valle E, De Crignis S, Cordischi VM, Fattapposta F, Rizzo PA, Pietravalle P, Cristina G, **Morano S**, Di Mario U. Abnormalities of cognitive functions in IDDM revealed by P300 Event-Related Potential Analysis. *Diabetes*,40,952-958,1991

- 19) Pietravalle P, **Morano S**, Cristina G, De Rossi MG, Mariani G, Cotroneo P, Ghirlanda G, Clementi A, Andreani D, Di Mario U. Charge selectivity of proteinuria in type 1 diabetes explored by immunoglobulin subclass clearance. *Diabetes*,40,12:1685-1690,1991
- 20) Di Mario U, Bacci S, **Morano S**, Pugliese G, Pietravalle P, Morabito S, Simonetti B, Andreani D, Pierucci A. Selective decrement of anionic immunoglobulin clearance after induced renal hemodynamic changes in diabetic patients. *Am J Physiol* 262:F381-388,1992
- 21) Sensi M, Pricci F, Pugliese C, De Rossi MG, Celi FS, Cristina A, Morano S, Andreani D, Di Mario U. Enhanced nonenzymatic glycation of eye lens proteins in experimental diabetes mellitus: an approach for the study of protein alterations as mediators of normal aging phenomena. *Arch Gerontol Geriatr.* 1992;15 Suppl 1:333-7.
- 22) Di Mario U, Romano R, **Morano S**, Pietravalle P. Clearance rate of immunoglobulins and diabetic nephropathy. *Acta Diabetol* 29,191-195,1992
- 23) **Morano S**, Pietravalle P, De Rossi MG, Mariani G, Cristina G, Medici F, Sensi M. Andreani D, Di Mario U. A charge selectivity impairment in protein permselectivity is present in type 2 diabetes. *Acta Diabetol* 30:138-142,1993
- 24) Pietravalle P, **Morano S**, Cristina G, Mancuso M, Valle E, Annulli M A, Tomaselli M, Pozzessere G, Di Mario U. Early complications in type 1 diabetes: central nervous system alterations precede kidney abnormalities. *Diab Res Clin Practice* 21:143-154,1993
- 25) Pietravalle P, **Morano S**, De Rossi MG, Mariani G, Cristina G, Ghirlanda G, Cotroneo P, Clementi A, Di Mario U. Protein charge permselectivity in type 2 and type 1 diabetes. In *Kidney, Proteins and Drugs: An Update. Contrib Nephrol.* Bianchi C, Bocci V, Carone FA, Rabkin R (eds). Basel, Karger, vol 101, pp 135-138,1993
- 26) **Morano S**, D'Erme M, Sensi M, De Rossi M G, Medici F, Galliccia F, Andreani D, Di Mario U. Characteristics of proteinuria in experimental diabetes mellitus. *Bioch Med Metab Biol* 53, 92-97, 1994 (now *Biochemical and Molecular Medicine*)
- 27) Sensi M, Pricci F, Pugliese G, De Rossi Mg, Cristina A, **Morano S**, Pozzessere G, Valle E, Andreani D, Di Mario U. Role of advanced glycation end-products (AGE) in late diabetic complications. *Diab Res Clin Practice* 28,9-17,1995
- 28) Di Mario U, **Morano S**, Valle E, Pozzessere G. Neuroelectrophysiological abnormalities in diabetes mellitus. *Diabetes Metabolism Reviews*, 11(3), 259-277,1995
- 29) **Morano S**, Sensi M, Pugliese G, Di Gregorio S, Pozzessere G, Petrucci AFG, Valle E, Caltabiano V, Vetri M, Di Mario U, Purrello F. Peripheral -but not central- nervous system abnormalities are reversed by pancreatic islet transplantation in diabetic Lewis rats. *Europ J Neurosci* 8, 1117-1123, 1996
- 30) Pietravalle P, Monteleone G, **Morano S**, Cristina G, De Rossi MG, Sagratella E, Biancone L, Parrello T, Oliva A, Pallone F, Di Mario U. Antineutrophil cytoplasmic antibodies are present in long standing type 1 diabetics but do not correlate with selective proteinuria. *J Autoimmunity* 9, 1, 113-117, 1996
- 31) Sensi M, **Morano S**, De Rossi MG, Celi FS, Cristina A, Valle E, Petrucci AFG, Sancesario G, Massa R, Pozzessere G, Di Mario U. Neuroelectrophysiological abnormalities are related to metabolic and advanced non-enzymatic glycation changes in prospectively evaluated diabetic rats. *Diabetes Nutrition & Metabolism* 10, 101-109, 1997
- 32) Sensi M, **Morano S**, Morelli S, Castaldo P, Sagratella E, De Rossi MG, Andreani D, Caltabiano V, Vetri M, Purrello F, Di Mario U. Reduction of advanced glycation end-product (AGE) levels in nervous tissue proteins of diabetic Lewis rats following islet transplants is related to different durations of poor metabolic control. *Eur J Neurosci* 10,2768-2775,1998
- 33) **Morano S**, Guidobaldi L, Cipriani R, Gabriele A, Pantellini F, Medici F, D' Erme M, Di Mario U. High glucose modifies heparansulphate synthesis by mouse glomerular epithelial cells. *Diab Metab Rev Res* 15:13-20, 1999.
- 34) Sensi M, **Morano S**, Valle E, Petrucci AFG, Pozzessere G, Caltabiano V, Vetri M, Purrello F, Andreani D, Di Mario U. Effect of islet transplantation on neuroelectrophysiological abnormalities in diabetic Lewis rats: comparison of primary versus secondary prevention. *Transplantation* 68(10):1453-1459, 1999
- 35) **Morano S**, Tiberti C, Cristina G, Sensi M, Cipriani R, Guidobaldi L, Torresi P, Medici F, Anastasi E, Di Mario U. Autoimmune markers and neurological complication in non-insulindependent diabetes mellitus. *Human Immunology* 60:848-854, 1999
- 36) Monteleone G, Cristina G, Parrello T, **Morano S**, Biancone L, Pietravalle P, Sagratella E, Doldo P, Luzzza F, Di Mario U, Pallone F. Altered IgG4 renal clearance in patients with inflammatory bowel disease. Evidence for a subclinical impairment of protein charge renal selectivity. *Nephrol Dial Transplant* 15(4):498-501, 2000
- 37) **Morano S**, Cipriani R, Gabriele A, Medici F, Pantellini F. Tumori bruni recidivanti come prima manifestazione di iperparatiroidismo primitivo. *Minerva Med* 91:117-122, 2000
- 38) Sensi M, **Morano S**, Sagratella E, Castaldo P, Morelli S, Vetri M, Caltabiano V, Purrello F, Andreani D, Vecchi E, Di Mario U. Advanced glycation end-product levels in eye lens proteins and aortic and tail tendon in transplanted diabetic inbred Lewis rats. *Transplantation* 72:1370-75, 2001
- 39) Rossi P, **Morano S**, Serrao M, Gabriele A, Di Mario U, Pozzessere G. Pre-perceptual pain sensory responses (N1 component) in type 1 diabetes mellitus. *NeuroReport* 13, 8:1-4, 2002
- 40) Pozzessere G, Rossi P, Gabriele A, R. Cipriani, Morocutti A, Di Mario U, **Morano S**. Early detection of small fiber neuropathy in diabetes: a laser-induced pain somatosensory evoked potentials and pupillometric study. *Diabetes Care*; 25 (12):2355-8, 2002
- 41) Buongiorno AM, Sagratella E, Morelli S, Bjerrum OJ, Maroccia E, Di Virgilio A, **Morano S**, Fallucca F, Di Mario U, Sensi M. Two pI clonal antisera detect different AGE epitopes in human plasma samples. *Immunology Letters* 85:243-249, 2003
- 42) **Morano S**. Pathophysiology of diabetic sexual dysfunction. *J Endocrinol Invest* 26 (suppl n. 3):65-69, 2003
- 43) **Morano S**, Cipriani R, Cerrito MG, Santangelo C, Vasaturo F, Pantellini F, Sensi M, Guidobaldi L, Scarpa S, Di Mario U. Angiotensin converting enzyme inhibitors modulate high glucose induced extracellular matrix changes in mouse glomerular epithelial cells. *Nephron Exp Nephrol* 95(1):e30-e35, 2003
- 44) Cipriani R, Sensi M, Mandosi E, Gatti A, Gabriele A, Di Mario U, **Morano S**. The impairment of renal function is not associated to altered circulating Vascular Endothelial Growth Factor in patients with type 2 diabetes and hypertension. *Diab Nutr Metab*, 17, 90-94, 2004 **IF 0.514** WOS:000221750300003 PMID 15244100 **IDS Number:** 825IP **ISSN:** 0394-3402

- 45) Iacobellis G, Cipriani R, Gabriele A, Di Mario U, **Morano S**. Circulating vascular endothelial growth factor is correlated with left ventricular function and geometry in patients with type 2 diabetes and hypertension. *Cytokines*, 27, 25-30, 2004
- 46) Tempera I, Cipriani R, Campagna G, Mancini P, Gatti A, Guidobaldi L, Pantellini F, Mandosi E, Sensi M, Di Mario U, D'Erme M, **Morano S**. Poly(ADP-ribose)polymerase activity is reduced in circulating mononuclear cells from type 2 diabetic patients. *J Cell Physiol*, 205, 387-392, 2005
- 47) Romeo S, Milione M, Gatti A, Fallarino M, Corleto V, **Morano S**, Baroni MG. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. *Horm Res* 65:120-5, 2006
- 48) **Morano S**, Gatti A, Mandosi E, Tiberti C, Fallarino M, Cipriani R, Buchetti B, Gandini L, Sgrò P, Lenti L, Lenzi A. Circulating monocyte oxidative activity is increased in patients with type 2 diabetes and erectile dysfunction. *J Urol* 177:655-659, 2007
- 49) **Morano S**, Mandosi E, Fallarino M, Gatti A, Tiberti C, Sensi M, Gandini L, Buchetti B, Lenti L, Jannini EA, Lenzi A. Antioxidant treatment associated to sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. *Eur Urol* 52:1768-76, 2007
- 50) De Mattia G, Bravi MC, Laurenti O, Moretti A, Cipriani R, Gatti A, Mandosi E, **Morano S**. Urinary Vascular Endothelial Growth Factor is inversely correlated to renal function in patients with type 2 diabetes. *Diabetes Res Clin Pract* 79(2):337-42, 2008
- 51) Gravina GL, Brandetti F, Martini P, Carosa E, Di Stasi SM, **Morano S**, Lenzi A, Jannini EA. Measurement of the thickness of the urethrovaginal space in women with or without vaginal orgasm. *J Sex Med.*;5(3):610-8, 2008
- 52) Vendrame F, Verrienti A, Parlapiano C, Filetti S, Dotta F, **Morano S**. Thyrotoxic periodic paralysis in an Italian male: clinical manifestation and genetic analysis. *Ann Clin Biochem* 45:218-220, 2008
- 53) **Morano S**, Cipriani R, Santangelo C, Fallarino M, Camevale A, Mandosi E, Gatti A, Sensi M and Di Mario U. Angiotensin converting enzyme inhibition and angiotensin II receptor-1 antagonism on extracellular matrix synthesis by glomerular epithelial cells in high glucose. *Clin Ter* 159(3):151-4, 2008
- 54) Buongiorno AM, Morelli S, Sagratella E, Cipriani R, Mazzaferro S, **Morano S**, Sensi M. Immunogenicity of advanced glycation end products (AGEs) in diabetic patients and in nephropathic non diabetic patients on hemodialysis or after kidney transplantation. *J Endocrinol Invest* 31(6):558-62, 2008
- 55) Gatti A, Baroni MG, Romeo S, Mandosi E, Fallarino M, Bezzi M, Paciucci L, Filetti S, **Morano S**. A case of severe occult ectopic adrenocorticotropin syndrome treated with retrograde venous adrenal ablation using ethanol. *J Endocrinol Invest*. 2008 Dec;31(12):1135-6.
- 56) Gatti A, Morini E, De Cosmo S, Maiani F, Mandosi E, **Morano S**, Trischitta V. Insulin resistance and the metabolic syndrome are not a risk factors for reduced kidney function in obese non diabetic individuals. *Obesity*, 16(4):899-901, 2008
- 57) Tiberti C, Shashaj B, Verrienti A, Vecci EG, Lucantoni F, Masotti D, **Morano S**, Sulli N, Dotta F. GAD and IA-2 autoantibody detection in type 1 diabetic patient saliva. *Clin Immunol*. 131, 271-6. 2009
- 58) Mandosi E, Fallarino M, Rossetti M, Gatti A, **Morano S**. Waist circumference reduction after insulin detemir therapy in type 2 diabetes patients previously treated with NPH. *Diabetes Res Clin Pract*. 84, e18-e20, 2009
- 59) Gatti A, Mandosi E, Fallarino M, Radicioni A, Morini E, Maiani F, Trischitta V, Lenzi A, **Morano S**. Metabolic Syndrome (MS) and Erectile Dysfunction (ED) among Obese non Diabetic Subjects. *J Endocrinol Invest*. 2009 Jun;32(6):542-5, 2009
- 60) Gatti A., Maranghi M, Bacci S, Carallo C, Gnasso A, Mandosi E, Fallarino M, **Morano S**, Trischitta V, Filetti S. Poor glycemic control is an independent risk factor for low HDL-C in patients with type 2 diabetes. *Diabetes Care*, 32(8), 1550-1552, 2009
- 61) Terzano C, **Morano S**, Ceccarelli D, Conti V, Paone G, Petroianni A, Graziani E, Carnovale A, Fallarino M, Gatti A, Mandosi E, Lenzi A. Effect of insulin on airway responsiveness in patients with type 2 diabetes mellitus: a cohort study. *J Asthma* 46(7), 703-707, 2009
- 62) Maranghi M, Pugliese F, Cianci R, Colotto M, Durante C, Anatra MG, Coletta P, Mercuri S, Rossetti M, **Morano S**, Filetti S. Atherosclerosis renal artery stenosis and in stent restenosis in diabetic patient: targeting on Diabetic Dyslipidemia is a key intervention. *J Endocrinol Invest*. 2010, 33(4):284-5.
- 63) Isidori AM, Pozza C, Esposito K, Giugliano D, **Morano S**, Vignozzi L, Corona G, Lenzi A, Jannini EA. Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. *J Sex Med*. 2010 Mar;7(3):1139-46.
- 64) Mandosi E, Fallarino M, Gatti A, Carnevale A, Rossetti M, Lococo E, Buchetti B, Lenti L, **Morano S**. Atorvastatin Downregulates Monocyte CD36 Scavenger Receptor Expression And Nuclear NFkB Levels In Type 2 Diabetic Patients. *J Atheroscler Thromb*. 2010 Jun 30;17(6):539-45
- 65) Cugini P, Amato S, Tarquini G, Mercuri S, Tirinese I, Tego A, Rossetti M, Panetti D, Filardi T, Curione M, **Morano S**. Studio della disautonomia cardiaca silente mediante monitoraggio ambulatorio della pressione arteriosa: diagnosi tramite la scomparsa del ritmo circadiano della frequenza cardiaca nei pazienti con diabete melito tipo 1. *Clin Ter* 161: e1-e10, 2010
- 66) Irace C, Rossetti M, Carallo C, **Morano S**, Vespertini V, Mandosi E, Maranghi M, Fiorentino R, Filetti S, Gnasso A. Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. *Acta Diabetol* 2011
- 67) Pugliese G, Solini A, Bonora E, Orsi E, Zerbini G, Giorgino F, Cavalot F, Pontiroli AE, Baroni MG, **Morano S**, Nicolucci A, Penno G. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation provides a better definition of cardiovascular burden associated with CKD than the Modification of Diet in Renal Disease (MDRD) Study formula in subjects with type 2 diabetes. *Atherosclerosis*. 2011 Sep;218(1):194-9. Epub 2011 May 6.
- 68) Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Cavalot F, Cignarelli M, Laviola L, **Morano S**, Nicolucci A, Pugliese G; for the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. *J Hypertens*. 2011 Sep;29(9):1802-1809.
- 69) Maranghi M, Prudente S, D'Erasmus L, Morini E, Ciociola E, Coletta P, Verrienti A, Arciello S, Copetti M, Pellegrini F, Santini SA,

- Morano S**, Filetti S, Trischitta V. The ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) K121Q polymorphism modulates the beneficial effect of weight loss on fasting glucose in non-diabetic individuals. *IF 3.502 U-GOV Nutr Metab Cardiovasc Dis*. 2013 Jun;23(6):505-10. doi: 10.1016/j.numecd.2011.11.003. Epub 2012 Mar 7. PMID:22402064
- 70)** Paladini F, Adinolfi V, Cocco E, Ciociola E, Tamburrano G, Cascino I, Lucantoni F, **Morano S**, Sorrentino R. Gender-dependent association of type 2 diabetes with the vasoactive intestinal peptide receptor 1. *Gene* 493 (2012) 278–281
- 71)** Giannetta E, Isidori A M; Galea N, Carbone I, Mandosi E, Vizza C D, Naro F, **Morano S**, Fedele F, Lenzi A. Chronic inhibition of cyclic GMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. *Circulation*. 2012 May 15;125(19):2323-33. doi: 10.1161/CIRCULATIONAHA.111.063412. Epub 2012 Apr 11. PMID: 22496161
- 72)** Tiberti C, Panimolle F, Bonamico M, Shashaj Blegin, Filardi T, Lucantoni F, Nenna R, Costantino F, Lenzi A, **Morano S**. IgA anti-transglutaminase autoantibodies at type 1 diabetes onset are less frequent in adult patients and are associated to a general celiac-specific lower immune response in comparison to non-diabetic celiac patients at diagnosis. *Diabetes Care*. 2012 Oct;35(10):2083-5. Epub 2012 Jul 18. doi: 10.2337/dc11-2171 PMID: 22815294
- 73)** Pugliese G, Solini A, Zoppini G, Fondelli C, Zerbini G, Vedovato M, Cavalot F, Lamacchia O, Buzzetti R, **Morano S**, Nicolucci A, Penno G. High prevalence of advanced retinopathy in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. *Diabetes Res Clin Pract*. 2012 Nov;98(2):329-37. doi: 10.1016/j.diabres.2012.09.006. Epub 2012 Sep 26. PMID: 23020932
- 74)** Penno G, Solini A, Zoppini G, Orsi E, Zerbini G, Trevisan R, Gruden G, Cavalot F, Laviola L, **Morano S**, Nicolucci A, Pugliese G, for the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. "Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes. The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study". *Diabetes Care* 35, 2317-2323, 2012
- 75)** Vaccaro O, Masulli M, Bonora E, Del Prato S, Giorda CB, Maggioni AP, Mocalelli P, Nicolucci A, Rivellesse AA, Squatrito S, Riccardi G; TOSCA.IT study group, including **Morano S**.(Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial). Addition of either pioglitazone or a sulphonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial. *Nutr Metab Cardiovasc Dis*. 2012 Nov;22(11):997-1006. doi: 10.1016/j.numecd.2012.09.003. Epub 2012 Oct 11.
- 76)** Zampetti S, Capizzi M, Spoleitini M, Campagna G, Leto G, Cipolloni L, Tiberti C, Bosi E, Falorni A, Buzzetti R; NIRAD Study Group, including **Morano S**. GADA titer-related risk for organ-specific autoimmunity in LADA subjects subdivided according to gender (NIRAD study 6). *J Clin Endocrinol Metab*. 2012 Oct;97(10):3759-65. doi: 10.1210/jc.2012-2037. Epub 2012 Aug 3..
- 77)** Morabito S, **Morano S**, Fallarino M, Gangemi C, Mandosi E, Pistolesi V, Rossetti M, Tarquini G, Turinese I, Onetti Muda A, Pierucci A. Un caso di ipotiroidismo associato a insufficienza renale reversibile e microematuria persistente. *Informer in Endocrinology* , 22, 34-37, 2013
- 78)** Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, **Morano S**, Cavalot F, Lamacchia O, Laviola L, Nicolucci A, Pugliese G; for the Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. HbA1c Variability As an Independent Correlate of Nephropathy, but Not Retinopathy, in Patients With Type 2 Diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. *Diabetes Care*. 2013 Aug;36(8):2301-10. doi: 10.2337/dc12-2264. Epub 2013 Mar 14. PMID: 23491522
- 79)** Penno G, Solini A, Zoppini G, Orsi E, Fondelli C, Zerbini G, **Morano S**, Cavalot F, Lamacchia O, Trevisan R, Vedovato M and Pugliese G. Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes. A cross-sectional analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. *Cardiovasc Diabetol*. 2013 Jul 5;12:98. doi: 10.1186/1475-2840-12-98. PMID: 23829205
- 80)** Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Trevisan R, Vedovato M, Cavalot F, Cignarelli M, **Morano S**, Ferrannini E, Pugliese G. Renal Insufficiency and Cardiovascular Events Study Group. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency And Cardiovascular Events Italian multicenter study. *J Am Geriatr Soc*. 2013 Aug;61(8):1253-61. doi: 10.1111/jgs.12381. Epub 2013 Jul 26. PMID: 23889588
- 81)** Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Laviola L, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) study, group. Collaborators (65, **Morano S. included**). Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study. *J Intern Med*. 2013 Aug;274(2):176-91. doi: 10.1111/joim.12073. Epub 2013 Apr 22. PMID: 23565931
- 82)** Barbarossa G, Renzi A, D'Erasmus L, Gallo A, Grieco E, Rossetti M, Carnovale A, Santilli M, Mandosi E, Coletta P, Pergolini D, **Morano S**, Maranghi M. The relation between glycaemic control and HDL-C in type 2 diabetes: a preliminary step forward? *Diabetes Res Clin Pract*. 2014 Apr;104(1):e26-8. doi: 10.1016/j.diabres.2013.12.061. Epub 2014 Jan 8. PMID: 24468098
- 83)** Curione M, Di Bona S, Amato S, Turinese I, Tarquini G, Gatti A, Mandosi E, Rossetti M, Varrenti M, Salvatore S, Baiocco E, **Morano S**. Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with secretagogues. *IF 2.784 Acta Diabetol*. 2014 Feb;51(1):31-3. doi: 10.1007/s00592-012-0438-6. Epub 2012 Nov 1. PMID:23114725
- 84)** Camevale V, **Morano S**, Romagnoli E, Annese MA, Fallarino M, Filardi T, Fontana A, Copetti M, Pellegrini F, Eller-Vainiche C, Zhukouskaya VV, Chiodini I, D'Amico G. Assessment of ten-year probability of fracture through the FRAX algorithm in men and women with and without type 2 diabetes mellitus. *Diabetes Metab Res Rev*. 2014 May;30(4):313-22. doi: 10.1002/dmrr.2497. PMID: 24420974
- 85)** Tiberti C, Panimolle F, Bonamico M, Filardi T, Pallotta L, Nenna R, Pontone S, Dotta F, Pugliese G, Lenzi A, Balducci S, **Morano S**. Long-standing type 1 diabetes: patients with adult-onset develop celiac-specific immunoreactivity more frequently than patients with childhood-onset diabetes, in a disease duration-dependent manner. *Acta Diabetol*. 2014 Jan 23. [Epub ahead of print] PMID: 24452477
- 86)** Pugliese G, Solini A, Bonora E, Orsi E, Zerbini G, Fondelli C, Gruden G, Cavalot F, Lamacchia O, Trevisan R, Vedovato M, Penno G; RIACE Study Group (**Morano S. included**). Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. *Cardiovasc Diabetol*. 2014 Mar 13;13(1):59. doi: 10.1186/1475-2840-13-59.

PMID: 24624891

- 87)** Pugliese G, Solini A, Bonora E, Fondelli C, Orsi E, Nicolucci A, Penno G; RIACE Study Group (including **Morano S**). Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. *Nutr Metab Cardiovasc Dis.* 2014 Aug;24(8):815-22. doi: 10.1016/j.numecd.2014.02.013. Epub 2014 Mar 1. PMID 24780515
- 88)** Zampetti S, Campagna G, Tiberti C, Songini M, Arpi ML, De Simone G, Cossu E, Cocco L, Osborn J, Bosi E, Giorgino F, Spoletini M, Buzzetti R; NIRAD Study Group. High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up **Morano S** (NIRAD study 7). *Eur J Endocrinol.* 2014 Dec;171(6):697-704. doi: 10.1530/EJE-14-0342. Epub 2014 Sep 11. PMID: 25213702
- 89)** **Morano S**, Romagnoli E, Filardi T, Nieddu L, Mandosi E, Fallarino M, Turinese I, Dagostino MP, Lenzi A, Carnevale V. Short-term effects of Glucagon-Like Peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. *Acta Diabetologica* Jan 2015 DOI: 10.1007/s00592-014-0710-z PMID: 25577244
- 90)** Bruttomesso D, Laviola L, Lepore G, Bonfanti R, Bozzetto L, Corsi A, Di Blasi V, Girelli A, Grassi G, Iafusco D, Rabbone I, Schiaffini R. Continuous Subcutaneous Insulin Infusion in Italy: Third National Survey. *Diabetes Technol Ther.* 2015 Feb;17(2):96-104. doi: 10.1089/dia.2014.0242. Epub 2014 Dec 5. PMID: 25479035
- 91)** Caputo S, Maran A, Mannino D, **Morano S**, Lastoria G, Nicoziani P. Safety and effectiveness of insulin detemir in combination with oral anti-diabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study. *Minerva Endocrinologica*, 40 (4);249-258, 2015 (IF 1.323) PMID: 26551483
- 92)** Mandosi E, Giannetta E, Filardi T, Lococo M, Bertolini C, Fallarino M, Gianfrilli D, Venneri MA, Lenti L, Lenzi A, **Morano S**. Endothelial dysfunction markers as therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes. *Expert Opinion on Therapeutic Targets*, 15, 1-6, 2015 PMID: 26178526
- 93)** Barchetta I, Capoccia D, Baroni MG, Buzzetti R, Cavallo MG, De Cosmo S, Leonetti F, Leotta S, **Morano S**, Morviducci L, Prudente S, Pugliese G, Trischitta V. The "Sapienza University Mortality and Morbidity Event Rate (SUMMER) Study in Diabetes": Study Protocol. *Nutrition, Metabolism & Cardiovascular Diseases* (2016) 26, 103-108 doi:10.1016/j.numecd.2015.09.009
- 94)** Tavaolione F, Filardi T, Fallarino M, Mandosi E, Turinese I, Rossetti M, Lenzi A, **Morano S**. The SNP rs9677 of VPAC1 gene is associated with glycolipid control and heart function in females with type 2 diabetes: a follow-up study. *Nutrition, Metabolism & Cardiovascular Diseases* (2016), 26, 109-113 <http://dx.doi.org/10.1016/j.numecd.2015.10.009>
- 95)** Pacilli A, Fallarino M, Massa M, Filardi T, De Cosmo S, **Morano S**, Trischitta V. Patient/disease features and glycemic targets in type 2 diabetes: where do we stand? *Acta Diabetologica*, 2016 Jan 11. [Epub ahead of print] No abstract available. PMID: 26754323
- 96)** Romagnoli E, Migliaccio S, Lubrano C, Carnevale V, **Morano S**, Costantini D, Gnessi L, Lenzi A. Assessment of trabecular bone score (TBS) in overweight/obese men: effect of metabolic and anthropometric factors. *Endocrine*. 2016 Jan 27. [Epub ahead of print] DOI 10.1007/s12020-016-0857-1 PMID: 26815904
- 97)** Santangelo C, Zicari A, Mandosi E, Scazzocchio B, Mari E, **Morano S**, Masella R. Could gestational diabetes mellitus be managed through dietary bioactive compounds? Current knowledge and future perspectives. *Br J Nutr.* 2016 Feb 16:1-16. [Epub ahead of print] PMID: 26879600
- 98)** Santangelo C, Filesi C, Vari R, Scazzocchio B, Filardi T, Fogliano V, D'Archivio M, Giovannini C, Lenzi A, **Morano S**, Masella R. Consumption of extra-virgin olive oil rich in phenolic compounds improves metabolic control in patients with type 2 diabetes mellitus: a possible involvement of reduced levels of circulating visfatin. *J Endocrinol Invest.* 2016 Jun 25. [Epub ahead of print] PMID:27344308
- 99)** Pallotta N, Filardi T, Carnovale A, Nieddu L, Mariani P, Vincoli G, Lenzi A, **Morano S**. Two-hour post-load glycemia is associated to an increased risk of NAFLD in healthy subjects with family history of type 2 diabetes: a case control study. *Endocrine* 2016 in press

Roma, 26 settembre 2016

